Depomed Inc: Shareholders Board Members Managers and Company Profile | US2499081048

Business description: Depomed Inc

Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Companyâs primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).

Sales by Activity: Depomed Inc

Fiscal Period: December	2019	2020	2021	2022	2023
Pharmaceuticals	230M	108M	111M	156M	152M

See all business segments

Geographical breakdown of sales: Depomed Inc

Fiscal Period: December	2019	2020	2021	2022	2023
United States	230M	108M	111M	156M	152M

See all geographic segments

Managers: Depomed Inc

Director	Title	Age	Since
Brendan O'Grady CEO	Chief Executive Officer	57	May. 28
Ajay Patel DFI	Director of Finance/CFO	40	19-06-30
Molly Dir ADM	Chief Administrative Officer	-	23-07-31
Howard Franklin CTO	Chief Tech/Sci/R&D Officer	-	23-03-05
William Iskos COO	Chief Operating Officer	-	21-07-31

See DEPOMED INC governance

Members of the board: Depomed Inc

Manager	Title	Age	Since
William McKee BRD	Director/Board Member	62	17-02-28
Heather Mason BRD	Director/Board Member	63	19-01-31
Peter Staple CHM	Chairman	72	03-10-31
Jeffrey Vacirca BRD	Director/Board Member	55	23-07-30
Sravan Emany BRD	Director/Board Member	46	Nov. 13
Sigurd Kirk BRD	Director/Board Member	57	Apr. 02
Brendan O'Grady CEO	Chief Executive Officer	57	May. 28

Composition of the Board of Directors

Shareholders: Depomed Inc

Name	Equities	%	Valuation
Nantahala Capital Management LLC 9.724 %	9,270,836	9.724 %	11 M $
Vanguard Global Advisers LLC 4.689 %	4,470,025	4.689 %	5 M $
Michael Gorzynski 4.022 %	3,834,214	4.022 %	5 M $
Renaissance Technologies LLC 2.494 %	2,377,614	2.494 %	3 M $
AQR Capital Management LLC 2.421 %	2,307,849	2.421 %	3 M $

List of DEPOMED INC shareholders

Company details: Depomed Inc

Assertio Holdings, Inc.

100 South Saunders Road Suite 300

60045, Lake Forest

+

http://www.assertiotx.com

Other Pharmaceuticals

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
ELI LILLY AND COMPANY	-0.19%	+3.57%	+50.89%	+293.12%	839B
NOVO NORDISK A/S	-0.04%	+2.09%	+16.03%	+153.66%	534B
JOHNSON & JOHNSON	+0.24%	+1.32%	+2.60%	+0.95%	389B
ABBVIE INC.	+0.82%	+1.09%	+32.93%	+79.70%	343B
MERCK & CO., INC.	+0.09%	+1.08%	+5.40%	+40.13%	278B
ROCHE HOLDING AG	+0.45%	+3.65%	+6.92%	-24.51%	252B
ASTRAZENECA PLC	+1.46%	+1.07%	+8.79%	+35.42%	238B
NOVARTIS AG	+0.86%	+2.63%	+15.02%	+31.18%	235B
AMGEN INC.	-0.46%	+2.76%	+13.71%	+57.76%	176B
Average	+0.39%	+2.19%	+16.92%	+74.16%	365.01B
Weighted average by Cap.	+0.27%	+2.84%	+22.79%	+117.70%

See all sector performances

Company Depomed Inc Nasdaq

Equities

US2499081048

Pharmaceuticals